Acute myeloid leukemia (AML) is a highly aggressive illness distinguished by the
accumulation of abnormal hematopoietic precursors in both the bone marrow and peripheral …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid
leukemia (AML) patients. These mutations lead to constitutive activation of the protein …

The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating
survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is …

FLT3 is a receptor tyrosine kinase with important roles in hematopoietic stem/progenitor cell
survival and proliferation. It is mutated in about 1/3 of acute myeloid leukemia (AML) …

FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3
mutations were discovered to have a role in AML. Several FLT3 inhibitors have been …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in
as few as 15%–40% of cases. Tremendous improvements in AML prognostication arose …

AML is a heterogeneous malignant clonal disorder with an overall incidence of 4.1 per
100,000 individuals. 1 The prognosis, although variable, is generally poor. Although the …

FLT3 mutations are the most common genomic alteration detected in acute myeloid
leukemia (AML) with a worse clinical prognosis. The highly frequent FLT3 mutations …

FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an
important role in hematopoietic cell survival, proliferation and differentiation. The most …